德琪醫藥(06996.HK)委任新首席醫學官
德琪醫藥(06996.HK)公布,由於退休原因,Kevin Patrick Lynch已辭任執行董事兼首席醫學官之職務,同時繼續擔任公司顧問之職務,自2022年12月16日起生效。同日起,張曉靜獲委任為首席醫學官。
張曉靜在腫瘤學領域和製藥行業擁有超過20年的經驗,在美國和中國為諾華中國和拜耳工作逾12年,期間被晉升為腫瘤學全球臨床負責人(GCL),為多款早期化合物的開發做出貢獻;最近曾擔任恆瑞醫藥(600276.SH)首席醫學官(腫瘤學)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.